Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

BACKGROUND: Central nervous system (CNS) metastases in patients with ALK-positive non-small cell lung cancer (NSCLC) are a cause of substantial morbidity and mortality. Although alectinib had demonstrated promising intracranial efficacy in several clinical trials, data were limited on its CNS activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Zihua, Xing, Puyuan, Hao, Xuezhi, Wang, Yan, Song, Xia, Shan, Li, Zhang, Cuiying, Liu, Ziling, Ma, Kewei, Dong, Guilan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764827/
https://www.ncbi.nlm.nih.gov/pubmed/35039026
http://dx.doi.org/10.1186/s12916-021-02207-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764827/
https://www.ncbi.nlm.nih.gov/pubmed/35039026
http://dx.doi.org/10.1186/s12916-021-02207-x

Ejemplares similares